Together with Acambis, Baxter is developing a third generation smallpox vaccine based on the strain Modified Vaccinia Ankara (MVA). MVA is an attenuated form of the current generation of smallpox vaccines and, as such, is expected to allow the safe inoculation of “at risk” individuals with weakened immune systems, who could otherwise not be vaccinated against smallpox.

 » Printversion